MaxCyte Q2 revenue $7.3M, down 15% YoY; net loss narrows; Genentech partnership signed

MAXCYTE, INC.

Q2 2026 total revenue $7.3M, down 15% YoY; core revenue $6.5M (-21%), SPL revenue $0.8M.
Net loss $8.9M vs $12.4M loss in Q2 2025; operating expenses down to $15.8M.
Cash and investments $141.9M at June 30, 2026; repurchased ~$5.5M under $10M program.
Reiterates FY2026 guidance: revenue $30-32M (core $25-27M, SPL ~$5M); cash ≥$130.5M.
In July 2026 signed first multi-platform technology license partnership with Genentech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.